Page 706 - Read Online

Rodinò et al. Mini-invasive Surg 2020;4:70 I http://dx.doi.org/10.20517/2574-1225.2020.55 Page 9 of 10

The patient was discharged after 3 days without peri-procedural complications. After 30 days, a follow-
up transthoracic echocardiogram showed mild MR and stable transvalvular gradients. One year later the
patient confirmed a clinical status improvement (NYHA functional class I-II) with no further hospital
admissions for heart failure.

DECLARATIONS
Authors’ contributions
Participated to the conception and the drafting of the manuscript, its critical revision for important
intellectual content and the final approval of the submitted text; agreed for all aspects of the work ensuring
that questions related to the accuracy or integrity of any part of the work are appropriately investigated and
resolved: Rodinò G, Masiero G, Tarantini G

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Tarantini G reports honoraria for lectures from Abbott Vascular and Edwards Lifesciences; Rodinò G and
Masiero G declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, et al. Burden of valvular heart diseases: a population-based study. Lancet
2006;368:1005-11.
2. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the
management of valvular heart disease. Eur Heart J 2017;38:2739-91.
3. Iung B. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur
Heart J 2003;24:1231-43.
4. Antoine C, Mantovani F, Benfari G, Mankad SV, Maalouf JF, et al. Pathophysiology of degenerative mitral regurgitation: new
3-Dimensional imaging insights. Circ Cardiovasc Imaging 2018;11:e005971.
5. Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J 2010;31:1958-66.
6. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med
1999;341:1-7.
7. Freed LA, Benjamin EJ, Levy D, Larson MG, Evans JC, et al. Mitral valve prolapse in the general population. J Am Coll Cardiol
2002;40:1298-304.
8. Kolibash AJ. Progression of mitral regurgitation in patients with mitral valve prolapse. Herz 1988;13:309-17.
9. Ma JI, Igata S, Strachan M, Nishimura M, Wong DJ, et al. Predictive factors for progression of mitral regurgitation in asymptomatic
patients with mitral valve prolapse. Am J Cardiol 2019;123:1309-13.
10. Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Détaint D, et al. What are the characteristics of patients with severe, symptomatic,
mitral regurgitation who are denied surgery? Eur Heart J 2007;28:1358-65.
11. De Bonis M, Lapenna E, Alfieri O. Edge-to-edge Alfieri technique for mitral valve repair: which indications? Curr Opin Cardiol
2013;28:152-7.